Le Lézard
Classified in: Health
Subject: NPT

Is Respiratory Compromise The New "Sepsis"?: Interview with Dr. Jeffrey Vender


CHICAGO, Oct. 19, 2017 /PRNewswire/ --The Physician-Patient Alliance for Health & Safety is pleased to announce the release of a clinical education podcast with Jeffrey S. Vender, MD.

Improving Health & Safety Through Innovation and Awareness. (PRNewsfoto/Physician-Patient Alliance...)

Jeffrey S. Vender, MD is Clinical Professor at the University Of Chicago, Pritzker School of Medicine. He is also Chairman of the clinical advisory committee to the Respiratory Compromise Institute.

The Respiratory Compromise Institute is a coalition of medical and safety organizations devoted to raising awareness about respiratory compromise. Members of the Respiratory Compromise Institute consist of representatives from leading medical and safety organizations:

The Respiratory Compromise Institute defines respiratory compromise as "a potentially life threatening state of unstable respiratory health." Respiratory Compromise "is a gradual, subtle imbalance in patient response that encompasses respiratory failure and arrest, with symptoms that manifest differently in each patient."

Dr. Vender believes that "there's been a lack of understanding of how to monitor better, or to recognize better, those patients at-risk." He encourages clinicians to do "a better job of monitoring and understanding the drugs we use in those patients at risk, so we can reduce these complications."

During the podcast, Dr. Vender discussed similarities with early stages of the campaign to raise awareness about sepsis:

"No different than when the Surviving Sepsis Campaign was developed for sepsis managed. Irrespective of one's perception of the materials provided or the evidence based medicine used, the Surviving Sepsis Campaign markedly increased clinician awareness of the problem for earlier diagnosis, much more acute intervention. And, today, whatever studies we look at the vast majority, even the control groups, for routine care have been markedly better as far as morbidity/mortality than the control groups of studies years gone by. And the reason for that is really just increased better care but more understanding and more awareness. Not necessarily a mandate of what to do."

To read a transcript of the interview, please click here.

The podcast with Dr. Vender may be viewed on the PPAHS YouTube channel by clicking here.

About Physician-Patient Alliance for Health & Safety

Physician-Patient Alliance for Health & Safety is a non-profit 501(c)(3) whose mission is to promote safer clinical practices and standards for patients through collaboration among healthcare experts, professionals, scientific researchers, and others, to improve healthcare delivery. For more information, please go to www.ppahs.org.

 

SOURCE Physician-Patient Alliance for Health & Safety


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: